Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Confirmed Best Overall Response Based on RECIST v1.1

From: Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

Response With Mitotane (n = 25) Without Mitotane (n = 25) Overall (N = 50)
Confirmed best overall response, n (%)
 Complete response 0 0 0
 Partial response 2 (8.0) 1 (4.0) 3 (6.0)
 Stable disease 10 (40.0) 11 (44.0) 21 (42.0)
 Progressive disease 10 (40.0) 13 (52.0) 23 (46.0)
 Not evaluable 3 (6.0) 0 3 (6.0)
ORR (95% CI), % 8.0 (1.0–26.0) 4.0 (0.1–20.4) 6.0 (1.3–16.5)
Disease control rate, % 48.0 48.0 48.0